Cullinan Therapeutics (CGEM) to Release Earnings on Thursday

Key Points

• Cullinan Therapeutics is set to announce its Q2 2025 earnings on August 14th, with analysts predicting an EPS of ($0.80).
• In its last earnings report, the company exceeded expectations, reporting an EPS of ($0.74) compared to analysts' consensus of ($0.78).
• Currently, Mullinan Therapeutics has a market cap of $465 million and an average stock rating of "Buy" with a target price of $30.00.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

Cullinan Therapeutics stock opened at $7.88 on Thursday. Cullinan Therapeutics has a 1 year low of $6.85 and a 1 year high of $19.89. The firm's 50-day moving average is $8.11 and its 200-day moving average is $8.43. The company has a market cap of $465.00 million, a P/E ratio of -2.71 and a beta of -0.08.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. UBS Group dropped their price target on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th. Finally, Stifel Nicolaus started coverage on Cullinan Therapeutics in a research note on Wednesday, June 11th. They issued a "buy" rating and a $22.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $30.00.

Institutional Investors Weigh In On Cullinan Therapeutics

Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of Cullinan Therapeutics in the first quarter worth approximately $618,000. Jane Street Group LLC increased its stake in shares of Cullinan Therapeutics by 145.9% in the first quarter. Jane Street Group LLC now owns 34,396 shares of the company's stock worth $260,000 after acquiring an additional 109,413 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cullinan Therapeutics during the first quarter worth $163,000. Institutional investors and hedge funds own 86.31% of the company's stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.